Tango Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
with Tango Therapeutics this morning. I'm Michael Schmidt, Senior Biotech Analyst with Guggenheim, and with us today we have Malte Peters, CEO of Tango. Malte, welcome and thanks for joining us.
Thanks, Michael, for having us. It's an honor to be here on a beautiful sunny morning in Boston, looking forward to the chat.
Great. It's been a very busy year so far for Tango, especially this fall. As you look at where the company is today, how would you describe the stage Tango is in now, and what are your top priorities as you look forward?
Yeah. Tango is in a full pre-submission, pre-commercial mode, and we have really done a lot of work since I joined in January as CEO to transform and evolve the company into a late-stage drug development, pre-approval, pre-commercial organization. We have added significant expertise to our team. We are focused extremely in a laser-sharp manner on execution, and we are very happy with the fact that we have data that allows us actually to think about getting a drug approved. I remember when I joined the board in 2018 of Tango, the company was a discovery organization. Nobody would have thought how soon the organization would evolve into a late-stage mature development organization, and here we are. I think all of us at Tango are extremely happy with where we are, and we are all walking in the same direction. We have the same goals.
We want to get vopimetostat approved, and that's what we come to work for.
Okay. You did have an important data presentation recently at ESMO. Maybe just remind us, what have you learned from this combination study with daraxonrasib and the updated ESMO data, and what gives you confidence now heading into phase III?
Yeah. Thanks. Remember, we started speaking about the data back in June. On June 8 was the first day when we disclosed the combination data. At that time, we had a denominator of 12 patients. At that time, we had a 92% response rate, and three months later, or four months later in October, we presented an update of that dataset with a denominator of 22 patients in pancreatic cancer. Out of 22 patients, we have now a response rate of 82%. We have four out of five patients with non-small cell lung cancer responding, so that makes an 81% response rate combining PDAC and non-small cell lung cancer patients. That's a very, very reassuring dataset, and the dataset is corroborated or reinforced or supported by the fact that the responses are very durable. So we have a PFS rate at nine months of 88%.
If you look at the second line patients only, not a single patient has progressed, so the curve is actually at the 100% mark, and we still have a very attractive and very favorable safety profile. We have no grade 3 rash, we have no grade 3 stomatitis and mucositis, and that's why we feel very strongly about the dataset, and that's why at ESMO, we disclosed our plan to start a frontline study, a phase III study in frontline pancreatic cancer in the first half of next year.
I think the combination worked broadly across KRAS MTAP double mutation patients, but I don't think there were KRAS G12D patients in the cohort specifically. How confident are you that the combination works there as well?
Yeah, that's true, because remember, the study is a two-arm study. We have the daraxonrasib combination arm, and we have the zoldonrasib combination arm, and so far, all of the G12D patients flowed into the zoldonrasib arm. But we have now put a handful of G12D patients on the daraxonrasib arm as well. It's a bit early to say what the efficacy is. We have no reason to really believe or assume that the responses will be any less than in the other mutations. That position is also supported by the fact that we have a very high efficacy rate in the G12R patients. So G12R patients are very difficult to treat. daraxonrasib monotherapy yields a 7% response rate in the R patients, and we have observed 50% response rate in these patients.
So we are very confident that we see a high degree of synergy in the G12D patients as well.
Yeah. True synergy is not very common, I think, in oncology drug development. We've seen it in the MEK BRAF space, where you see synergy. But I guess, is there a mechanistic explanation that could explain why this combination is so synergistic?
There's no real one mechanism where we say, "Okay, that's the secret to explain the synergy." We know that the pathways are interacting and that the degree of synergy is tightly related to where the drugs actually operate in these pathways. Our preclinical experiments suggested a high degree of synergy, and we are super happy that we could confirm the synergy in the clinic, which, as you know, sometimes is not the case, right? You can have extremely encouraging data in the laboratory, which then fail to translate in the clinic. In our case, we actually confirmed the synergy in the clinical experiments, in the clinical setting of the study.
Can you remind us what you've seen in combination with zoldonrasib, the G12D inhibitor? In general, the mutant selective inhibitors have been generating higher response rates on their own than the pan-RAS inhibitors. Just curious, what are your thoughts on that other part of your combination study?
Yeah. If you look at the waterfall plot of the zoldonrasib combination, it's still extremely attractive, but the response rates are lower than in the daraxonrasib curve. We think we understand why. We think we need to hit the RAS wild-type component of the whole pathway, and we think we do this very effectively with daraxonrasib and not as strongly with zoldonrasib. So, we think we understand why there's a difference in response rate between daraxonrasib combination with vopi and zoldonrasib with vopi.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
